Glucose metabolic dysfunction in subjects with a Clinical Dementia Rating of 0.5

Journal of the Neurological Sciences

Volumn 215, Issue 1-2, 2003, Pages 71-74

  Ishii, Kazunari ^a   Mori, Tetsuya ^a   Hirono, Nobutsugu ^a   Mori, Etsuro ^a  

^a Hyogo Brain and Heart Center   (Japan)

Author keywords

Alzheimer's disease; Clinical Dementia Rating; Fluorodeoxyglucose (FDG); Positron emission tomography (PET)

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CINGULATE GYRUS; CLINICAL ARTICLE; CONTROLLED STUDY; DEMENTIA; FEMALE; GLUCOSE BRAIN LEVEL; GLUCOSE METABOLISM; HUMAN; MALE; METABOLIC DISORDER; PARIETAL LOBE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RATING SCALE; STATISTICAL PARAMETERS;

EID: 0142058150     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-510X(03)00206-5     Document Type: Article

References (15)

1. Petersen R.C., Doody R., Kurz A.et al. Current concepts in mild cognitive impairment. Arch. Neurol. 58:2001;1985-1992.
2. Petersen R.C., Stevens J.C., Ganguli M., Tangalos E.G., Cummings J.L., DeKosky S.T. Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 56:2001;1133-1142.
3. Morris J.C. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 43:1993;2412-2414.
4. Morris J.C. Clinical dementia rating: a reliable and valid diagnostic and staging measure for dementia of the Alzheimer type. Int. Psychogeriatr. 9(Suppl. 1):1997;173-176.
5. Zaudig M. A new systematic method of measurement and diagnosis of "mild cognitive impairment" and dementia according to ICD-10 and DSM-III-R criteria. Int. Psychogeriatr. 4(Suppl. 2):1992;203-219.
6. Morris J.C., Storandt M., Miller J.P.et al. Mild cognitive impairment represents early-stage Alzheimer disease. Arch. Neurol. 58:2001;397-405.
7. Petersen R.C. Mild cognitive impairment or questionable dementia? Arch. Neurol. 57:2000;643-644.
8. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS/ADRDA Work Group under the auspices of department of Health and Human Service Task Force on Alzheimer's disease. Neurology. 34:1984;939-944.
9. Ishii K., Sasaki M., Kitagaki H.et al. Reduction of cerebellar glucose metabolism in advanced Alzheimer's disease. J. Nucl. Med. 38:1997;925-928.
10. 18F-FDG PET in Alzheimer's disease: validation of anatomic standardization for atrophied brains. J. Nucl. Med. 42:2001;548-557.
11. Hoffman J.M., Welsh-Bohmer K.A., Hanson M.et al. FDG PET imaging in patients with pathologically verified dementia. J. Nucl. Med. 41:2000;1920-1928.
12. Minoshima S., Giordani B., Berent S., Frey K.A., Foster N.L., Kuhl D.E. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann. Neurol. 42:1997;85-94.
13. Herholz K., Salmon E., Perani D.et al. Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. NeuroImage. 17:2002;302-316.
14. Johnson K.A., Lopera F., Jones K.A.et al. Presenilin-1-associated abnormalities in regional cerebral perfusion. Neurology. 56:2001;1545-1551.
15. Reiman E.M., Caselli R.J., Yun L.S.et al. Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N. Engl. J. Med. 334:1996;752-758.